The purpose of this study is to evaluate the processes within the brain that can affect how head and neck cancer patients think and feel about how they look and feel after treatment. Participation in this study involves completing some questionnaires and undergoing one fMRI scan, which typically lasts one hour. It is hoped that the information gained from the study will help improve care for patients with head and neck cancer.
This study is for patients who have been diagnosed with Head and Neck Squamous Cell Carcinoma (HNSCC). The investigational drug used in this study is Ficlatuzumab. The main goals of this research study is to study the safety and effectiveness of Ficlatuzumab with or without Cetuximab, to determine which strategy will be more effective, as well as to learn the potential side effects of Ficlatuzumab alone or in combination with Cetuximab. It is unknown exactly how long participants can expect to be in the study. Subjects will receive treatment until the drug is no longer effective on their cancer.
The purpose of this study is to evaluate whether a new patient navigation intervention can decrease delays starting radiation therapy after surgery for white and African-American head and neck cancer patients. Patients who have surgery and radiation for certain types of head and neck cancer are eligible for this study.
The study is sponsored by the Medical University of South Carolina and Hollings Cancer Center. The investigator in charge of this study is Evan Graboyes, MD.
The study is being done at one site: the Medical University of
Approximately 45 subjects will take part at MUSC.
The purpose of this research study is to see if it is possible to collect tissue, saliva and blood samples from patients who are having surgery and send those samples to different labs across MUSC. The researchers in these labs will collect tissue, blood and saliva samples before surgery and during surgery to see if there are any changes in the samples. They will compare the changes in the samples to the clinical outcomes.
The objective of this study is to determine potential factors that contribute to late-stage diagnosis and treatment of HPV-positive and HPV-negative oropharyngeal tumors. We have developed a voluntary survey that will be given to patients treated at the MUSC Head and Neck Tumor Center. The survey consists of subsections that identify general HPV knowledge, timeline to diagnosis and treatment, educational background, and sociodemographic characteristics. The participating patients will be given the Short Test of Functional Health Literacy (S-TOFHLA) with the survey. The survey and health literacy data will be used to assess correlations between these factors and the patients stage of cancer at diagnosis. This study will also compare a chart review of prospective patients with retrospective chart review of former oropharyngeal cancer patients. The chart review will include data such as: stage of cancer at diagnosis, treatment, sequence of intervention for diagnosis and treatment, type of biopsy, and types of doctors involved in diagnosis and treatment.
The purpose of this study is to see whether an investigational drug called CDX-3379 combined with cetuximab, a monoclonal antibody that targets a protein called EGFR, will shrink tumors for subjects with head and neck squamous cell carcinoma (HNSCC). This study is for patients who have been diagnosed with HNSCC and who have previously received cetuximab but who have since experienced progression. Both the investigational drug, CDX-3379, and cetuximab are administered intravenously (into a vein). Subjects can expect to participate in the study for 2 years or longer.
This study is for patients that have been diagnosed with stage III-IVB Head and Neck cancer. The investigational drug in this study is MEDI4736 (Durvalumab). The purpose of the safety lead-in portion of the study is to determine whether adding the study drug MEDI4736 to radiation is safe in patients with head and neck cancer who cannot take the drug cisplatin. The purpose of the phase II/III portion is to compare any good and bad effects of usual radiation plus the study treatment, MEDI4736 (durvalumab), to the usual therapy of radiation plus cetuximab in patients with head and neck cancer who cannot take the drug cisplatin. Participants in the safety lead-in portion can expect to be in this study for approximately 2.5 years. Participants in the Phase II/III portion can expect to be in the study for up to 32 weeks, and then followed by their study doctor to monitor for side effects every year.
Body image disturbance (BID) is a self-perceived negative change in appearance and or function. Head and neck cancer is associated with BID since head and neck cancer (HNC) involves cosmetically and functionally important areas. BID in HNC patients is common and causes anxiety, depression, social isolation and decreased quality of life. Unfortunately, there is little information with regards to BID in HNC patients. Current research is limited by the lack of a HNC specific BID scale and instead relies on BID scales created for other cancer subsites. Thus, a measurement scale made specifically for BID in HNC patient is needed. The objective of this project is to create and validate a BID scale specific to HNC patients.
Arising in cosmetically and functionally critical areas, head and neck cancer and its treatments commonly cause life-altering changes in appearance, swallowing, and speaking. These changes affect body function and quality of life. Body image disturbance, a displeasing change in appearance or function noted by the patient, is common in head and neck cancer patients and causes stress, anxiety, and isolation in these patients. Unfortunately, there is not a lot of data on the topic. Treatments of body image disturbance for head and neck cancer patients remain unknown preventing us from providing patients with the best cancer care. This study will evaluate the effects of a type of therapy on body image disturbance in head and neck cancer patients undergoing surgery.
Delays in starting radiation after surgery for head and neck cancer disproportionately affect minorities and those of low socioeconomic status, causing increased mortality. The barriers that prevent the delivery of timely, equitable postoperative radiation remain unknown. This study seeks to identify the barriers to timely, equitable postoperative radiation following surgery for head and neck cancer.